| Revision as of 02:53, 14 December 2010 editDcirovic (talk | contribs)Autopatrolled, Extended confirmed users, Pending changes reviewers, Rollbackers253,275 editsNo edit summary← Previous edit | Revision as of 19:47, 13 January 2011 edit undoEdgar181 (talk | contribs)Extended confirmed users196,325 editsm moved SCH-530,348 to Vorapaxar: current generic drug nameNext edit → |
| (No difference) | |
Revision as of 19:47, 13 January 2011
 | This article is an orphan, as no other articles link to it. Please introduce links to this page from related articles; try the Find link tool for suggestions. (February 2009) |
 | |
| Identifiers | |
|---|---|
IUPAC name
| |
| CAS Number | |
| PubChem CID | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.116.767  |
| Chemical and physical data | |
| Formula | C29H33FN2O4 |
| Molar mass | 492.58 g/mol g·mol |
SCH-530,348 is a thrombin receptor (PAR-1) antagonist based on the natural product himbacine. Developed by Schering-Plough, SCH-530,348 is a potential treatment for acute coronary syndrome chest pain caused by coronary artery disease.
Now owned by Merck, this compound is being called Vorapaxar.
References
- Samuel Chackalamannil (2008). "Discovery of a Novel, Orally Active Himbacine-Based Thrombin Receptor Antagonist (SCH 530348) with Potent Antiplatelet Activity". Journal of Medicinal Chemistry. 51: 3061. doi:10.1021/jm800180e.
| Antithrombotics (thrombolytics, anticoagulants and antiplatelet drugs) (B01) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Antiplatelet drugs |
| ||||||||||||||
| Anticoagulants |
| ||||||||||||||
| Thrombolytic drugs/ fibrinolytics | |||||||||||||||
| Non-medicinal | |||||||||||||||
| |||||||||||||||